A Fort Washington pharmaceutical company's stock opened up 9% Monday after it posted positive early stage clinical trial results from testing of its antibiotic Xenleta as a potential treatment for cystic fibrosis.
Nabriva Therapeutics' stock was trading up about 13% at $2.45 per share in early morning trading.
Cystic fibrosis is a progressive, genetic disease that causes severe damage to the lungs, digestive system, and other organs. It can cause frequent lung infections including pneumonia or…
